MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Saved in:
Bibliographic Details
Title: MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.
Authors: Hurvitz N; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Amitai I; Hematology Division, Chaim Sheba Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Yurkovski IL; Hematology Division, Bnai Zion Medical Canter, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel., Tvito A; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel., Ofran Y; Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Hebrew University Jerusalem, Jerusalem, Israel., Porges T; Institute of Hematology, Soroka University Medical Center, Beer Sheva, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel., Sherban A; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Gray Faculty of Medical & Health Sciences, Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel., Even-Zohar NG; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Vainstein V; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Haran A; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Aumann S; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Mikhelashvili R; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Frisch A; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Nachmias B; Leukemia Service, Department of Hematology, Hadassah Medical Center and, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. BoazN@hadassah.org.il.
Source: Annals of hematology [Ann Hematol] 2026 May 09; Vol. 105 (7). Date of Electronic Publication: 2026 May 09.
Publication Type: Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0584
DOI:10.1007/s00277-026-07054-5